<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02376699</url>
  </required_header>
  <id_info>
    <org_study_id>SGNS40-001</org_study_id>
    <secondary_id>PN 863</secondary_id>
    <nct_id>NCT02376699</nct_id>
  </id_info>
  <brief_title>Safety Study of SEA-CD40 in Cancer Patients</brief_title>
  <official_title>A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seagen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seagen Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to find out if SEA-CD40 is safe and effective when given alone, in&#xD;
      combination with pembrolizumab, and in combination with pembrolizumab, gemcitabine, and&#xD;
      nab-paclitaxel. The study will test increasing doses of SEA-CD40 given at least every 3 weeks&#xD;
      to small groups of patients. The goal is to find the highest dose of SEA-CD40 that can be&#xD;
      given to patients that does not cause unacceptable side effects. Different dose regimens will&#xD;
      be evaluated. Different methods of administration may be evaluated. The pharmacokinetics,&#xD;
      pharmacodynamic effects, biomarkers of response, and antitumor activity of SEA-CD40 will also&#xD;
      be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted in the following parts:&#xD;
&#xD;
      Part A: Intravenous (IV) monotherapy dose-regimen finding for solid tumors --&#xD;
      Dose-escalation, and possible dose-interval modification to lengthen the treatment cycle, to&#xD;
      define the IV SEA-CD40 monotherapy maximum tolerated dose (MTD) and/or the optimal biological&#xD;
      dose (OBD) regimens in patients with solid tumors. The ability to increase the dose intensity&#xD;
      (to give additional doses within a treatment cycle) may be evaluated.&#xD;
&#xD;
      Part B: IV monotherapy solid tumor expansion cohorts -- Disease-specific solid tumor&#xD;
      expansion cohorts may be enrolled where patients will be treated with doses at or below the&#xD;
      IV SEA-CD40 monotherapy MTD and/or OBD determined in Part A.&#xD;
&#xD;
      Part C: IV monotherapy dose-regimen finding for lymphomas -- Dose-escalation, and possible&#xD;
      dose-interval modification to lengthen the treatment cycle, to define the IV SEA-CD40&#xD;
      monotherapy MTD and/or the OBD regimens in patients with lymphomas. The ability to increase&#xD;
      the dose intensity (to give additional doses within a treatment cycle) may be evaluated.&#xD;
&#xD;
      Part D: IV monotherapy lymphoma expansion cohorts -- Disease-specific lymphoma expansion&#xD;
      cohorts may be enrolled where patients will be treated with doses at or below the IV SEA-CD40&#xD;
      monotherapy MTD and/or OBD determined in Part C.&#xD;
&#xD;
      Part E: Combination therapy dose-regimen finding for solid tumors -- IV SEA-CD40&#xD;
      dose-escalation to define the MTD and/or the OBD regimen to be administered in combination&#xD;
      with standard approved dose of pembrolizumab in patients with solid tumors.&#xD;
&#xD;
      Part F: Combination therapy solid tumor expansion cohorts -- Disease-specific solid tumor&#xD;
      expansion cohorts may be enrolled where patients will be treated with IV SEA-CD40 and&#xD;
      pembrolizumab combination therapy; doses of SEA-CD40 will be at or below the MTD and/or OBD&#xD;
      determined in Part E.&#xD;
&#xD;
      Part G: Subcutaneous (SC) injection (injected under the skin) monotherapy dose-regimen&#xD;
      finding for solid tumors -- Dose-escalation, and possible dose-interval modification to&#xD;
      lengthen the treatment cycle, to define the SC SEA-CD40 monotherapy maximum tolerated dose&#xD;
      (MTD) and/or the optimal biological dose (OBD) regimens in patients with solid tumors.&#xD;
&#xD;
      Part H: SC monotherapy solid tumor expansion cohorts -- Disease-specific solid tumor&#xD;
      expansion cohorts may be enrolled where patients will be treated with doses at or below the&#xD;
      SC SEA-CD40 monotherapy MTD and/or OBD determined in Part G.&#xD;
&#xD;
      (Note: There is no Part I)&#xD;
&#xD;
      Part J: SC monotherapy dose-regimen finding for lymphomas -- Dose-escalation, and possible&#xD;
      dose-interval modification to lengthen the treatment cycle, to define the SC SEA-CD40&#xD;
      monotherapy MTD and/or the OBD regimens in patients with lymphomas.&#xD;
&#xD;
      Part K: SC monotherapy lymphoma expansion cohorts -- Disease-specific lymphoma expansion&#xD;
      cohorts may be enrolled where patients will be treated with doses at or below the SC SEA-CD40&#xD;
      monotherapy MTD and/or OBD determined in Part J.&#xD;
&#xD;
      Part L: Combination therapy in pancreatic cancer -- Patients will be treated with SEA-CD40&#xD;
      doses at or below MTD and/or OBD. An established dose of pembrolizumab and a standard regimen&#xD;
      of gemcitabine and nab-paclitaxel will be used.&#xD;
&#xD;
      In Parts A, C, E, G, and J, a maximum feasible dose (MFD) will be defined if an MTD and/or&#xD;
      OBD cannot be identified. Parts B, D, F, H, K. and L will explore the recommended dosing&#xD;
      regimen once the MTD and/or OBD, or MFD (if the MTD and/or OBD cannot be identified) has been&#xD;
      determined.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 28, 2015</start_date>
  <completion_date type="Anticipated">February 29, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (Parts A-K)</measure>
    <time_frame>Through 6 weeks following last dose, up to an average of 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of laboratory abnormalities (Parts A-K)</measure>
    <time_frame>Through 6 weeks following last dose, up to an average of 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR) per RECIST according to investigator assessment in the efficacy-evaluable population (Part L)</measure>
    <time_frame>Through 6 weeks following last dose, up to an average of 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (Part L)</measure>
    <time_frame>Through 6 weeks following last dose, up to an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR per iRECIST (Part L)</measure>
    <time_frame>Through 6 weeks following last dose, up to an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR (Parts A-K)</measure>
    <time_frame>Through 6 weeks following last dose, up to an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (All Parts)</measure>
    <time_frame>Through 6 weeks following last dose, up to an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (All Parts)</measure>
    <time_frame>Up to approximately 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (All Parts)</measure>
    <time_frame>Up to approximately 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (All Parts)</measure>
    <time_frame>Up to approximately 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum observed concentration)</measure>
    <time_frame>Through 6 weeks following last dose, up to an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax (time of maximum observed concentration)</measure>
    <time_frame>Through 6 weeks following last dose, up to an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast (AUC from time 0 to last quantifiable timepoint)</measure>
    <time_frame>Through 6 weeks following last dose, up to an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf (AUC from time 0 to infinity)</measure>
    <time_frame>Through 6 weeks following last dose, up to an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total clearance</measure>
    <time_frame>Through 6 weeks following last dose, up to an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 (apparent terminal elimination half-life)</measure>
    <time_frame>Through 6 weeks following last dose, up to an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of antitherapeutic antibodies against SEA-CD40</measure>
    <time_frame>Through 6 weeks following last dose, up to an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood concentrations of SEA-CD40</measure>
    <time_frame>Through 6 weeks following last dose, up to an average of 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Carcinoma, Squamous Cell</condition>
  <condition>Hodgkin Disease</condition>
  <condition>Lymphoma</condition>
  <condition>Lymphoma, B-Cell</condition>
  <condition>Lymphoma, Follicular</condition>
  <condition>Lymphoma, Large B-Cell, Diffuse</condition>
  <condition>Melanoma</condition>
  <condition>Neoplasm Metastasis</condition>
  <condition>Neoplasms, Head and Neck</condition>
  <condition>Neoplasms, Squamous Cell</condition>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Non-Small Cell Lung Cancer Metastatic</condition>
  <condition>Non-small Cell Carcinoma</condition>
  <condition>Squamous Cell Cancer</condition>
  <condition>Squamous Cell Carcinoma</condition>
  <condition>Squamous Cell Carcinoma of the Head and Neck</condition>
  <condition>Squamous Cell Neoplasm</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>IV Monotherapy in Solid Tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEA-CD40 administered IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Monotherapy in Lymphomas</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEA-CD40 administered IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Therapy in Solid Tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEA-CD40 (administered IV) + pembrolizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SC Monotherapy in Solid Tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEA-CD40 administered SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SC Monotherapy in Lymphomas</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEA-CD40 administered SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Therapy in Pancreatic Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEA-CD40 (administered IV) + pembrolizumab + gemcitabine + nab-paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous (IV) SEA-CD40</intervention_name>
    <description>Given intravenously; schedule is cohort-specific.</description>
    <arm_group_label>Combination Therapy in Pancreatic Cancer</arm_group_label>
    <arm_group_label>Combination Therapy in Solid Tumors</arm_group_label>
    <arm_group_label>IV Monotherapy in Lymphomas</arm_group_label>
    <arm_group_label>IV Monotherapy in Solid Tumors</arm_group_label>
    <other_name>SEA-CD40</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Given intravenously; schedule is cohort-specific.</description>
    <arm_group_label>Combination Therapy in Pancreatic Cancer</arm_group_label>
    <arm_group_label>Combination Therapy in Solid Tumors</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Subcutaneous (SC) SEA-CD40</intervention_name>
    <description>Given subcutaneously on Day 1 every 3 weeks</description>
    <arm_group_label>SC Monotherapy in Lymphomas</arm_group_label>
    <arm_group_label>SC Monotherapy in Solid Tumors</arm_group_label>
    <other_name>SEA-CD40</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1000 mg/m^2 given intravenously on Day 1, 8, and 15 of each 28-day cycle</description>
    <arm_group_label>Combination Therapy in Pancreatic Cancer</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>125 mg/m^2 given intravenously on Day 1, 8, and 15 of each 28-day cycle</description>
    <arm_group_label>Combination Therapy in Pancreatic Cancer</arm_group_label>
    <other_name>Abraxane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  (Monotherapy - Parts A, B, C, D, G, H, J, and K) -- Histologically confirmed advanced&#xD;
             malignancy, either: (a) Metastatic or unresectable solid malignancy; or (b) Classical&#xD;
             Hodgkin lymphoma (HL), or diffuse large B-cell lymphoma (DLBCL), or indolent lymphoma&#xD;
             (including follicular lymphoma [FL])&#xD;
&#xD;
          -  (Monotherapy - Parts A, B, C, D, G, H, J, and K) -- Relapsed, refractory, or&#xD;
             progressive disease, specifically: (a) Solid tumors: Following at least 1 prior&#xD;
             systemic therapy, and no further standard therapy is available for the patient's&#xD;
             advanced solid tumor at the time of enrollment; or (b) Classical HL: Following at&#xD;
             least 2 prior systemic therapies in patients who are not candidates for autologous&#xD;
             stem cell transplant (SCT), or following failure of autologous SCT; or (c) DLBCL:&#xD;
             Following at least 1 prior systemic therapy; patients must have also received&#xD;
             intensive salvage therapy unless they refused or were deemed ineligible; or (d)&#xD;
             Indolent lymphoma: Following at least 1 prior chemoimmunotherapy regimen that included&#xD;
             an anti-CD20 monoclonal antibody and for which no other more appropriate treatment&#xD;
             option exists&#xD;
&#xD;
          -  (Combination Therapy - Part E and Part F) -- Histologically or cytologically confirmed&#xD;
             advanced or metastatic solid malignancy for which pembrolizumab treatment is approved.&#xD;
             In Part F, other advanced solid tumor indications may be eligible as identified by the&#xD;
             Sponsor.&#xD;
&#xD;
          -  (Pancreatic Cancer Cohort - Part L) - Histologically or cytologically confirmed&#xD;
             metastatic exocrine ductal adenocarcinoma of the pancreas not amenable to curative&#xD;
             therapy. Patients must not have received any prior systemic therapy for metastatic&#xD;
             disease; patients who have received prior therapy for non-metastatic pancreatic&#xD;
             adenocarcinoma are eligible if therapy was fully completed more than 4 months before&#xD;
             start of study treatment.&#xD;
&#xD;
          -  Representative baseline tumor tissue sample is available (Parts A-K)&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  Adequate baseline hematologic, renal, and hepatic function&#xD;
&#xD;
          -  Recovery to Grade 1 of any clinically significant toxicity attributed to prior&#xD;
             anticancer therapy prior to initiation of study drug administration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Parts A-K&#xD;
&#xD;
               1. Prior chemotherapy, small molecule inhibitors, and/or other investigational&#xD;
                  anticancer agents (excluding investigational monoclonal antibodies) within 4&#xD;
                  weeks&#xD;
&#xD;
               2. Prior radiotherapy: therapeutic radiotherapy within 4 weeks, or palliative&#xD;
                  radiotherapy (to non-CNS disease) within 1 week&#xD;
&#xD;
               3. Prior immune-checkpoint inhibitors within 4 weeks (or 8 weeks, if immuno-oncology&#xD;
                  doublet used as the prior line of therapy)&#xD;
&#xD;
               4. Prior monoclonal antibodies, antibody-drug conjugates, or radioimmunoconjugates&#xD;
                  within 4 weeks (or 2 weeks if patient experienced disease progression on the&#xD;
                  prior treatment)&#xD;
&#xD;
               5. Prior T-cell or other cell-based therapies within 12 weeks (or 2 weeks if patient&#xD;
                  experienced disease progression on the prior treatment)&#xD;
&#xD;
          -  Part L&#xD;
&#xD;
               1. History of radiation pneumonitis&#xD;
&#xD;
               2. Neuropathy Grade 2 or higher&#xD;
&#xD;
               3. Has received prior therapy with an anti-PD-1, anti-PDL1, or anti-PD-L2 agent,&#xD;
                  with an agent directed to another stimulatory or co-inhibitory T-cell receptor&#xD;
&#xD;
               4. Has had allogenic tissue/solid organ transplant&#xD;
&#xD;
          -  All Parts&#xD;
&#xD;
               1. Recent or ongoing serious infections within 2 weeks&#xD;
&#xD;
               2. Known positivity for hepatitis B infection&#xD;
&#xD;
               3. Known active hepatitis C infection&#xD;
&#xD;
               4. Active autoimmune or auto-inflammatory ocular disease within 6 months&#xD;
&#xD;
               5. Known or suspected active organ-threatening autoimmune disease&#xD;
&#xD;
               6. Active central nervous system tumor or metastases&#xD;
&#xD;
          -  Patients with lymphomas: prior allogeneic SCT&#xD;
&#xD;
          -  Patients in Part E, F, or L: history of severe immune-mediated adverse reactions or&#xD;
             severe hypersensitivity to pembrolizumab&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Schmitt, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Seagen Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HonorHealth Scottsdale Shea Medical Center</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center / Samuel Oschin Comprehensive Cancer Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Angeles Clinic and Research Institute, The</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute / Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center / University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University / University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center / University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Cancer Specialists</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance / University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 17, 2015</study_first_submitted>
  <study_first_submitted_qc>February 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2015</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CD40 Antigen</keyword>
  <keyword>Drug Therapy</keyword>
  <keyword>Follicular Lymphoma</keyword>
  <keyword>Hodgkin Disease</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Indolent Lymphoma</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Lymphoma, B-Cell</keyword>
  <keyword>Lymphoma, Large B-Cell, Diffuse</keyword>
  <keyword>Lymphoma, Non-Hodgkin</keyword>
  <keyword>Monoclonal Antibody</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Neoplasm Metastasis</keyword>
  <keyword>Solid tumor</keyword>
  <keyword>Seattle Genetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Neoplasms, Squamous Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

